Date of application of new EU In Vitro Diagnostics Regulation
26 May 2022 marks the date of application of the new EU In Vitro Diagnostics Regulation (EU) 2017/746 and with it the most transformative regulatory framework impacting in vitro diagnostics in Europe.

Today marks the date of application of the new EU In Vitro Diagnostics Regulation (EU) 2017/746 and with it the most transformative regulatory framework impacting in vitro diagnostics in Europe.

We at Critical Catalyst welcome and celebrate this important milestone in the diagnostics field!

Our team will continue to lead the way on regulatory affairs support to in vitro diagnostics manufacturers, ensuring that vital diagnostic solutions comply with the requirements on safety and performance and remain available to healthcare professionals and patients.

Regulatory background

Medical devices, including in vitro medical devices, have a fundamental role in saving lives by providing healthcare solutions for the diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of a disease.
Regulation (EU) 2017/746 (IVDR) replaces Directive 98/79/EC (IVDD) and significantly reinforces the regulatory framework applicable to in vitro diagnostic medical devices.

Application of new In Vitro Diagnostics Regulation

As of today, new rules on in vitro diagnostic medical devices such as HIV tests, pregnancy tests or COVID-19 tests, will be applicable, aiming to better protect public health and patient safety in respect to these devices, bringing EU law in line with technological progress and medical advances. By aligning market access requirements in the different EU Member States, it also boosts a free and fair market access for manufacturers.

In summary, the new Regulation on in vitro diagnostic medical devices introduces several important advances:
– Improves the quality, safety and reliability of in vitro diagnostic medical devices with a new risk-based device classification system;

– More detailed and stringent rules on the evaluation of device performance;

– Greater involvement of independent conformity assessment bodies (‘notified bodies’). Additionally, panel of experts and EU reference laboratories can be involved in the assessment of the highest-risk in vitro diagnostics;

– A unique device identifier will be mandatory for every IVD to reinforce traceability through EUDAMED;

– For medium and high risk devices a Summary of Safety and Performance will be made publicly available;

– Enhances vigilance and post-market surveillance, with manufacturers having to proactively collect data about their performance and EU authorities closely coordinating their vigilance and market surveillance activities.

Some important notes:

Although five years have passed since the new IVDR first came into force, there are still some key aspects that are not fully in place concerning the sufficient infrastructure to support the new regulation, and in particular, the limited Notified Body capacity, which is why the regulation was amended in January 2022 to grant many existing IVDs a further three to five more years to transition to the new requirements. Regarding requirements application, the in vitro diagnostics are divided in three IVD categories, to which the IVDR applies differently:

– Old devices (devices placed on the market under the IVDD before the date of application);

– New devices (devices placed on the market under the IVDR, regardless of the date of application); and

– Legacy devices (devices with an IVDD CE certificate valid past the date of application and IVDD devices with a valid declaration of conformity issued before the date of application).

Regardless, the folowing requirements apply from 26 May 2022:

From 26 May 2022 all IVD manufacturers must:

– Update QMS to meet the IVDR.

– Update design control to include General Safety and Performance Requirements for new devices and significant changes.

– Implement Chapter VII of the IVDR post-market requirements including PMS Plan, PMS Report, PMPF and vigilance with trend reporting.

– Clinical performance studies according to Annex XII and XIV as appropriate and address ISO 20916.

– Appoint a Person Responsible for Regulatory Compliance (PRRC) before placing IVDs on the market under the IVDR.

– Register in EUDAMED, when applicable.

References:

Regulation (EU) 2017/746 on in vitro diagnostic medical devices.

MDCG 2022-8 – Regulation (EU) 2017/746 – application of IVDR requirements to ‘legacy devices’ and to devices placed on the market prior to 26 May 2022.


further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »